Sanofi India Limited has announced its Q4 financial results for the quarter ended March 31, 2026, showing mixed performance with declining revenue but maintained profitability. The pharmaceutical company also announced significant board changes with the completion of tenure for two independent directors.

Financial Performance Overview

The company's Q4 performance reflected challenges in revenue generation while maintaining operational efficiency. Despite revenue pressures, Sanofi India preserved healthy profit margins during the quarter.

Revenue and Profitability Analysis

Sanofi India's revenue performance showed a notable decline of 12%, falling to ₹4.72B in Q4 compared to ₹5.36B in the corresponding quarter of the previous year. Total income also declined to ₹4.77B from ₹5.39B year-on-year, reflecting broader market challenges.

Net profit decreased to ₹1.03B from ₹1.20B in the same period last year, representing a 14% decline. Earnings per share also declined to ₹44.55 from ₹51.89 year-on-year, impacting shareholder returns for the quarter.

Strategic Business Performance

Despite overall revenue challenges, the company's insulin portfolio delivered exceptional performance, achieving double-digit growth versus both the previous year and previous quarter. Managing Director Deepak Arora highlighted that the insulin segment registered 19% growth versus last year and 14% growth versus the previous quarter, demonstrating Sanofi's established equity in the diabetes injectable segment.

The company's strategic partnerships in cardiovascular, oral anti-diabetes, and central nervous system segments have established a robust foundation for future growth. However, overall results were impacted by transactions relating to partnership transitions.

Board Changes and Leadership Transition

The Board of Directors meeting held on April 28, 2026, approved significant governance changes effective from April 29, 2026. The tenure of Mr. Aditya Narayan and Mrs. Usha Thorat as independent directors will be completed from the close of business hours on April 29, 2026.

Mr. Rahul Bhatnagar has been appointed as the Chairman of the Board effective from April 30, 2026. The board placed on record its appreciation for the invaluable contributions and services rendered by the departing directors during their association with the company.

Committee Restructuring

Following the leadership changes, the company announced the re-constitution of all major committees effective from April 30, 2026. This includes comprehensive restructuring of the Audit Committee, Nomination and Remuneration Committee, Stakeholders Relationship Committee, Risk Management Committee, and Corporate Social Responsibility Committee to ensure continued effective governance and oversight.

Sanofi India has announced several important corporate decisions, including the scheduling of its 70th Annual General Meeting and a significant dividend recommendation for shareholders.

Annual General Meeting Schedule

The pharmaceutical company's board has scheduled the 70th Annual General Meeting for April 29, 2026. This milestone AGM will mark seven decades of the company's operations and shareholder engagement.

Dividend Recommendation

The board has recommended a final dividend of ₹48 per share for shareholders. This dividend recommendation will be subject to approval at the upcoming AGM.

Board Composition Changes

Sanofi India will strengthen its board structure with the appointment of a new independent director, effective April 1, 2026. This appointment comes ahead of the 70th AGM and demonstrates the company's commitment to robust corporate governance.

The timing of these announcements reflects the company's systematic approach to corporate planning, with the director appointment preceding the AGM by nearly a month, allowing for proper integration before the shareholder meeting.